#Introduction to Clyra Medical Technologies' New Milestone
On February 9, 2026, BioLargo, Inc., a company focused on clean technology and life sciences, announced that its subsidiary, Clyra Medical Technologies, secured its first commercial stocking order for ViaCLYR™, an FDA-cleared wound irrigation solution. This order from Advanced Solution, LLC, marks a significant advancement in Clyra's transition from a development-phase organization to one poised for early revenue generation.
#Details of the Commercial Stocking Order
The initial order signifies the commencement of distribution, paving the way for ViaCLYR™ to be accessible through Advanced Solution's national distribution network. This will facilitate the product's availability to hospitals, clinics, and other healthcare providers across the United States, enhancing its reach and potential impact.
#About ViaCLYR™ and its Benefits
ViaCLYR™ is specially formulated for both acute and chronic wounds, as well as burns. Its unique characteristics include a clear, odorless solution that is non-irritating and highly effective, demonstrating over 99.9999% antimicrobial activity for up to 72 hours. This high efficacy supports its usage as a critical tool in advanced wound care.
#Strategic Insights and Future Plans
Steve Harrison, Chief Executive Officer of Clyra, noted that this stocking order reflects the culmination of extensive development and regulatory efforts. BioLargo’s Chairman, Dennis P. Calvert, emphasized that this event ratifies the company's strategy of introducing differentiated technologies to commercial markets via robust partnerships. The initiative sets the stage for future revenue and further commercialization efforts as Clyra expands its product portfolio.
#Background of Clyra Medical Technologies
Founded in 2012, Clyra Medical Technologies has been dedicated to the development and commercialization of advanced wound care solutions based on proprietary Copper-Iodine Complex Technology. The company aims to leverage its FDA-cleared medical devices to provide enhanced outcomes for patients through innovative product offerings.
#Key Takeaways
- Clyra Medical Technologies has received its first commercial stocking order for the ViaCLYR™ wound irrigation solution.
- This marks the transition from development to generating early revenue, enhancing its market position.
- ViaCLYR™ features a unique formulation effective in treating acute and chronic wounds with sustained antimicrobial activity.
- Strategic partnerships are critical to the distribution plan, promoting wider access across healthcare facilities in the U.S.
- Future initiatives will likely include the exploration of new products and expanded market presence.
Original source: Read original article